Leiden based Amplio Pharma B.V. has successfully closed a Seed investment round to execute a proof-of-principle clinical trial of its candidate drug product NovoBioJect in patients with rheumatoid arthritis. NovoBioJect has the potential to significantly improve the global pharmaceutical care of patients with autoimmune diseases. In this novel drug product, the PK enhancer novobiocin has the potential to lead to a faster onset of disease remission in a larger patient population. Achieving this objective not only translates in a decreased disease burden but also has the potential to save billions of euro’s on an annual basis, in support of a more sustainable healthcare.